| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study
|
Sangalli, F.
|
|
2010
|
31 |
supplement-3 |
p. 299-302
|
artikel
|
| 2 |
Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report
|
Florio, Ciro
|
|
2010
|
31 |
supplement-3 |
p. 325-327
|
artikel
|
| 3 |
Natalizumab efficacy on cognitive impairment in MS
|
Mattioli, F.
|
|
2010
|
31 |
supplement-3 |
p. 321-323
|
artikel
|
| 4 |
Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report
|
Rinaldi, F.
|
|
2010
|
31 |
supplement-3 |
p. 317-320
|
artikel
|
| 5 |
Natalizumab: state of the art and open questions
|
Comi, G.
|
|
2010
|
31 |
supplement-3 |
p. 313-315
|
artikel
|
| 6 |
Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome
|
Prosperini, L.
|
|
2010
|
31 |
supplement-3 |
p. 303-307
|
artikel
|
| 7 |
Swedish natalizumab (Tysabri) multiple sclerosis surveillance study
|
Piehl, Fredrik
|
|
2010
|
31 |
supplement-3 |
p. 289-293
|
artikel
|
| 8 |
The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases
|
Bruno, Valeria
|
|
2010
|
31 |
supplement-3 |
p. 283-288
|
artikel
|
| 9 |
The cohort of the multiple sclerosis center of Cagliari
|
Marrosu, M. G.
|
|
2011
|
31 |
supplement-3 |
p. 309-312
|
artikel
|
| 10 |
Three years of experience: the Italian registry and safety data update
|
Mancardi, G. L.
|
|
2010
|
31 |
supplement-3 |
p. 295-297
|
artikel
|
Tijdschrift beschrijving